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The efﬁcacy of Radiosurgery (RS), whether or not combined
with Whole Brain Radiotherapy, is well known in the treat-
ment of patients with a reduced number of brain metastases
(1–3). However, there is still no consensus on the efﬁcacy of RS
as a treatment in patients who have 4 or more brain metas-
tases, and their treatment, on many occasions, is reduced to
the administration of Whole Brain Radiotherapy only.
In an extensive review of the literature published in the
Journals of Neurosurgery and Radiation Oncology, including
the RTOG 9508 and ASTRO reports published in 2004 and 2005,
it is considered that patients who have 4 or more brain metas-
tases have a poor disease prognosis, and are treated with
whole brain radiotherapy. In none of these studies or reports
is it explained why this “magic” number 4, and not 3 or 5.
What does this number demonstrate?
• More brain dissemination?
• More extra-cerebral disseminated disease?
• More difﬁcult techniques?
• Or perhaps, it is a random number?
Aims of radiosurgery in brain metastases:
• To control the neurological deﬁcit.
• To prolong survival.
• To reduce neurological morbidity.
There is no doubt that the higher the number of brain
metastases the lower is the patient survival. However, this
relationship is not so obvious if we look at the morbidity and
cerebral toxicity.
Overall survival is considerably signiﬁcant, with a median
of almost 12 months and an acceptable quality of life. This,
although less ifwe compare it to singlemetastasis group, leads
us to believe that combined treatment with whole brain radio-
therapy and radiosurgery may be the treatment of choice in
patients with multiple metastases.
Those of us who work in the brain radiosurgery ﬁeld must
bear in mind that there are two unavoidable concepts: the
volume and the dose.
The mean volume in the case of the multiple metastases
group is less than in the patient group with one, two or three
brain metastases, since the lesions are smaller in the ﬁrst
group, and the majority of patients had received combined
treatment with whole brain radiotherapy.
In the multiple metastases group, the number of lesions
has not limited us to administering the effective therapeutic
dose. It is possible that the maximum dose could be high, but
it has not been assessed.
We do not know at what brain volume a neurological deﬁcit
is produced on administering a dose of 1000–800 cGy, (there
are some indications not related with Radiosurgery) or what
is the brain volume limit that would prevent us from perform-
ing radiosurgery treatment in this group of patients with ≥4
metastases. However, if we take less than 3 cm diameter as
the criterion to treat lesions, we estimate that lesions around
14 cm3 could be treated.
In our study, the mean was ≈2 cm3 and without knowing
the effects of the maximum dose, the toxicity obtained was
acceptable.
Noël and Mazeron (Bull Cancer 2004;91(1):81–93) in their
review of brain metastases put forward as an obstacle
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the long time that the patient has to be strictly speak-
ing on treatment (on the machine) which according Suzuki
et al, is between 2 and 11h (mean 5h). However, tech-
nical or administrative difﬁculties or barriers must not
be a greater obstacle than the medical beneﬁts that are
obtained.
Take, as an example, the unquestionable success assumed
from the improvement in the overall survival of patients with
glioblastoma multiforme, with a median of 12 months, and
why not with multiple brain metastases?
Based on these results and in other publications, we may
summarise that:
• The number “4” must not prevent the radical treatment of
brain metastases with radiosurgery.
o This is not associated with extra-cerebral tumour dis-
semination.
o It is not associated with greater morbidity.
o It is not associated with a more difﬁcult technique.
o There is directly proportional relationship between the
prognosis and the metastasis number, the higher the
brain metastasis number the worse is the prognosis (sim-
ilar to the performed literature review).
• The therapeutic decision should be associated with the
prognostic factor, the RPA and the individual assessment
of each case.
• The total PTV could affect the therapeutic decision.
• The administration of multiple RS treatments improves
patient survival and their quality of life.
Assuming as treatment criteria:
• Patients with RPA 1.
• Life expectancy greater than 6 months.
• Primary diseases controlled or controllable.
• Total PTV less than 14 cm3.
• Assess organs at risk, trunk and basal ganglia.
We strongly believe that we have to personalize the treat-
ment of the patients with brain oligometastases.
A new era is coming; multiple brain metastases can be
treated with Radiosurgery.
